Literature DB >> 19706150

Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.

C Pothoulakis1.   

Abstract

BACKGROUND: Saccharomyces boulardii, a well-studied probiotic, can be effective in inflammatory gastrointestinal diseases with diverse pathophysiology, such as inflammatory bowel disease (IBD), and bacterially mediated or enterotoxin-mediated diarrhoea and inflammation. AIM: To discuss the mechanisms of action involved in the intestinal anti-inflammatory action of S. boulardii.
METHODS: Review of the literature related to the anti-inflammatory effects of this probiotic.
RESULTS: Several mechanisms of action have been identified directed against the host and pathogenic microorganisms. S. boulardii and S. boulardii secreted-protein(s) inhibit production of proinflammatory cytokines by interfering with the global mediator of inflammation nuclear factor kappaB, and modulating the activity of the mitogen-activated protein kinases ERK1/2 and p38. S. boulardii activates expression of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) that protects from gut inflammation and IBD. S. boulardii also suppresses 'bacteria overgrowth' and host cell adherence, releases a protease that cleaves C. difficile toxin A and its intestinal receptor and stimulates antibody production against toxin A. Recent results indicate that S. boulardii may interfere with IBD pathogenesis by trapping T cells in mesenteric lymph nodes.
CONCLUSIONS: The multiple anti-inflammatory mechanisms exerted by S. boulardii provide molecular explanations supporting its effectiveness in intestinal inflammatory states.

Entities:  

Mesh:

Year:  2008        PMID: 19706150      PMCID: PMC2761627          DOI: 10.1111/j.1365-2036.2009.04102.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  57 in total

1.  Shiga toxin produced by enterohemorrhagic Escherichia coli inhibits PI3K/NF-kappaB signaling pathway in globotriaosylceramide-3-negative human intestinal epithelial cells.

Authors:  Alain P Gobert; Marjolaine Vareille; Anne-Lise Glasser; Thomas Hindré; Thibaut de Sablet; Christine Martin
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

Review 2.  Mitogen-activated protein kinase pathways.

Authors:  M J Robinson; M H Cobb
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

3.  Recruitment of cytoskeletal and signaling proteins to enteropathogenic and enterohemorrhagic Escherichia coli pedestals.

Authors:  D L Goosney; R DeVinney; B B Finlay
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  [Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells].

Authors:  Sang Kil Lee; Hyo Jong Kim; Sung Gil Chi; Jae Young Jang; Ki Deok Nam; Nam Hoon Kim; Kwang Ro Joo; Seok Ho Dong; Byung Ho Kim; Young Woon Chang; Joung Il Lee; Rin Chang
Journal:  Korean J Gastroenterol       Date:  2005-05

5.  Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes.

Authors:  K K Jefferson; M F Smith; D A Bobak
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

Review 6.  The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection.

Authors:  C Jobin; R B Sartor
Journal:  Am J Physiol Cell Physiol       Date:  2000-03       Impact factor: 4.249

7.  Mechanisms of tissue damage in inflammatory bowel disease.

Authors:  F Pallone; G Monteleone
Journal:  Curr Opin Gastroenterol       Date:  2001-07       Impact factor: 3.287

8.  Enterohemorrhagic Escherichia coli infection induces interleukin-8 production via activation of mitogen-activated protein kinases and the transcription factors NF-kappaB and AP-1 in T84 cells.

Authors:  Stephanie Dahan; Valere Busuttil; Veronique Imbert; Jean-Francois Peyron; Patrick Rampal; Dorota Czerucka
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

9.  Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes.

Authors:  Guillaume Dalmasso; Françoise Cottrez; Véronique Imbert; Patricia Lagadec; Jean-François Peyron; Patrick Rampal; Dorota Czerucka; Hervé Groux; Arnaud Foussat; Valerie Brun
Journal:  Gastroenterology       Date:  2006-12       Impact factor: 22.682

10.  Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study.

Authors:  K Plein; J Hotz
Journal:  Z Gastroenterol       Date:  1993-02       Impact factor: 2.000

View more
  39 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

Review 2.  The human mycobiome.

Authors:  Patrick C Seed
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

3.  A Pragmatic Approach to Immunity & Respiratory Viral Infections.

Authors:  Todd A Born
Journal:  Integr Med (Encinitas)       Date:  2020-10

4.  Saccharomyces boulardii reduces the mean intensity of infection in mice caused by the consumption of liver contaminated by Toxocara canis.

Authors:  Paula Dutra Cardoso; Débora Liliane Walcher; Priscila da Silva Cadore; Ana Carolina Beheregaray; Luis Augusto Xavier Cruz; Gabriel Baracy Klafke; Lourdes Helena Rodrigues Martins; João Luis Rheingantz Scaini; Luciana Farias da Costa de Avila; Fabricio Rochedo Conceição; Carlos James Scaini
Journal:  Parasitol Res       Date:  2019-12-17       Impact factor: 2.289

Review 5.  The intestinal microbiota and chronic disorders of the gut.

Authors:  Andrew W DuPont; Herbert L DuPont
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-16       Impact factor: 46.802

6.  Apoptotic Effect of Saccharomyces cerevisiae on Human Colon Cancer SW480 Cells by Regulation of Akt/NF-ĸB Signaling Pathway.

Authors:  Sara Shamekhi; Jalal Abdolalizadeh; Alireza Ostadrahimi; Seyyed Abolghasem Mohammadi; Abolfazl Barzegari; Hajie Lotfi; Esat Bonabi; Nosratollah Zarghami
Journal:  Probiotics Antimicrob Proteins       Date:  2020-03       Impact factor: 4.609

7.  Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice.

Authors:  Thomas W Hoffmann; Hang-Phuong Pham; Chantal Bridonneau; Camille Aubry; Bruno Lamas; Camille Martin-Gallausiaux; Marco Moroldo; Dominique Rainteau; Nicolas Lapaque; Adrien Six; Mathias L Richard; Emilie Fargier; Marie-Emmanuelle Le Guern; Philippe Langella; Harry Sokol
Journal:  ISME J       Date:  2015-07-28       Impact factor: 10.302

Review 8.  Novel approaches to treating Clostridium difficile-associated colitis.

Authors:  David Padua; Charalabos Pothoulakis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-07       Impact factor: 3.869

9.  Probiotics for the treatment of Clostridium difficile associated disease.

Authors:  Leo R Fitzpatrick
Journal:  World J Gastrointest Pathophysiol       Date:  2013-08-15

10.  Saccharomyces boulardii improves intestinal epithelial cell restitution by inhibiting αvβ5 integrin activation state.

Authors:  Alexandra Canonici; Emilie Pellegrino; Carole Siret; Chloé Terciolo; Dorota Czerucka; Sonia Bastonero; Jacques Marvaldi; Dominique Lombardo; Véronique Rigot; Frédéric André
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.